Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esculentin-2CHa-GA30
- Development stage
- Preclinical
- Lead developer
- Queen's University Belfast
- Modality
- Peptides
- Administration
- Intraperitoneal
01
Overview
esculentin-2CHa-GA30 (also known as esculentin-2CHa(1-30)) is a 30-amino acid truncated peptide derived from the host-defense peptide esculentin-2CHa, which was originally isolated from the skin secretions of the Chiricahua leopard frog (*Lithobates chiricahuensis*). Lacking the cyclic C-terminal domain of the native peptide, esculentin-2CHa-GA30 is designed for improved ease of synthesis and reduced cytotoxicity while retaining potent insulinotropic activity. It stimulates insulin secretion from pancreatic beta cells through a mechanism involving cell membrane depolarization and an increase in intracellular calcium levels, without directly inhibiting K-ATP channels. Developed by researchers at Ulster University and Queen's University Belfast, esculentin-2CHa-GA30 and its synthetic analogues are being investigated as potential therapeutic agents for the treatment of type 2 diabetes, obesity-related diabetes, and non-alcoholic fatty liver disease (NAFLD).
- Other names
- GA30GA-30GA 30esculentin-2CHa(1-30)esculentin-2CHa(GA30)
Beyond the preview
Go deeper on esculentin-2CHa-GA30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esculentin-2CHa-GA30.